SCHEMBL721291

SCHEMBL721291

COC(=O)c1ccc(N)cn1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.65
KDM4E B2RXH2 3/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
GAA P10253 2/20 0.44
LCK P06239 1/20 0.44
ALDH1A1 P00352 3/20 0.43
GLA P06280 1/20 0.43
GABRP O00591 2/20 0.42
GABRD O14764 2/20 0.42
GABRA1 P14867 2/20 0.42
GABRB1 P18505 2/20 0.42
GABRG2 P18507 2/20 0.42
GABRB3 P28472 2/20 0.42
GABRA5 P31644 2/20 0.42
GABRA3 P34903 2/20 0.42
GABRA2 P47869 2/20 0.42
GABRB2 P47870 2/20 0.42
GABRA4 P48169 2/20 0.42
GABRE P78334 2/20 0.42
GABRA6 Q16445 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31359497 1.00 MAPK1 (0.65) MAPK1KDM4EL3MBTL1GAALCK
Hydrochloric Acid SCHEMBL14125808 0.98 MAPK1 (0.62) MAPK1KDM4EL3MBTL1GAALCK
SCHEMBL7942053 0.89 MAPK1 (0.53) MAPK1KDM4EL3MBTL1GAALCK
SCHEMBL254303 0.86 MAPK1 (0.57) MAPK1KDM4EL3MBTL1ALDH1A1HSD17B10
SCHEMBL38656583 0.86 MAPK1 (0.57) MAPK1KDM4EL3MBTL1ALDH1A1HSD17B10
Hydrochloric Acid SCHEMBL6345836 0.84 MAPK1 (0.56) MAPK1KDM4EL3MBTL1LCKALDH1A1
SCHEMBL3235643 0.84 MAPK1 (0.46) MAPK1KDM4EL3MBTL1GAAALDH1A1
SCHEMBL10163267 0.83 MAPK1 (0.54) MAPK1KDM4EL3MBTL1ALDH1A1CYP3A4
SCHEMBL11635977 0.82 MAPK1 (0.53) MAPK1KDM4EL3MBTL1GAAALDH1A1
SCHEMBL796214 0.81 MAPK1 (0.44) MAPK1KDM4EL3MBTL1GABRPGABRD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 510 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119874681-A Indole derivative, preparation method thereof and application of indole derivative in resisting liver cancer 中国人民解放军北部战区总医院 2025-04-25 CN claimed
US-20240092773-A1 DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES UCB Biopharma SRL (BE) 2024-03-21 US claimed
CN-116554092-A Method for preparing new drug building block (6-formylpyridin-3-yl) carbamic acid tert-butyl ester 上海锐谱医药科技有限公司 2023-08-08 CN claimed
WO-2021130257-A1 DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES UCB Biopharma SRL (BE) 2021-07-01 WO claimed
US-20260124222-A1 ISOTHIAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS INC (US) 2026-05-07 US disclosed
US-20260116887-A1 HETEROCYCLIC COMPOUNDS FOR MEDIATING TYROSINE KINASE 2 ACTIVITY GUANGZHOU INNOCARE PHARMA TECH CO LTD (CN) 2026-04-30 US disclosed
EP-4699607-A2 N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS Vertex Pharmaceuticals Incorporated (US) 2026-02-25 EP disclosed
US-20260001870-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2026-01-01 US disclosed
US-12509451-B2 Heteroaryl amide inhibitors of CD38 NAPA THERAPEUTICS LIMITED (IM) 2025-12-30 US disclosed
EP-4652161-A1 2,4-DIANILINOPYRIMIDINE-BASED AURORA-A KINASE SELECTIVE DEGRADATION INDUCING COMPOUNDS Uppthera, Inc. (KR) 2025-11-26 EP disclosed
US-20250353836-A1 N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMA (US) 2025-11-20 US disclosed
US-20250353854-A1 FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN BIOMEA FUSION INC (US) 2025-11-20 US disclosed
US-4638068-A 2-(2-imidazolin-2-yl)-pyridines and quinolines, process and intermediates for the preparation thereof, and use of said compounds as herbicidal agents AMERICAN CYANAMID COMPANY (US) 1987-01-20 US disclosed
US-4528296-A Derivatives of aminopyridinecarboxylic acids and pharmaceutical compositions containing them SIMES, SOCIETA ITALIANA MEDICINALLE SINTETICI (IT) 1985-07-09 US disclosed
EP-0110484-A1 Derivatives of aminopyridinecarboxylic acids, methods for their preparation and pharmaceutical compositions containing them Simes S.p.A. (IT) 1984-06-13 EP disclosed
US-4273779-A Treating hypertension with substituted-5-amino-2-pyridinecarboxylic acids CIBA-GEIGY CORPORATION (US) 1981-06-16 US disclosed
US-4260620-A HYPOTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1981-04-07 US disclosed
US-4202901-A HYPOTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1980-05-13 US disclosed
US-4197302-A HYPOTENSIVE AGENTS, 5-ETHERIFIED, ALSO ESTERS, AMIDES, HYDRAZIDES CIBA-GEIGY CORPORATION (US) 1980-04-08 US disclosed
US-4036965-A HYPOTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1977-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240092773-A1 DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES FCER2, FCGR2A, FCGR1A MAPK1 4005/4885KDM4E 1663/4885L3MBTL1 4878/4885
US-20260116887-A1 HETEROCYCLIC COMPOUNDS FOR MEDIATING TYROSINE KINASE 2 ACTIVITY TYK2, JAK2, JAK1 MAPK1 74/4885KDM4E 951/4885L3MBTL1 3358/4885
US-20260001870-A1 INHIBITOR COMPOUNDS CES1, NCEH1, NR1H2 MAPK1 1857/4885KDM4E 3025/4885L3MBTL1 1210/4885
US-12509451-B2 Heteroaryl amide inhibitors of CD38 CD38, FCGRT, BCL6 MAPK1 1541/4885KDM4E 2756/4885L3MBTL1 2612/4885
US-20250353854-A1 FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN MEN1, MLLT1, MSI2 MAPK1 1983/4885KDM4E 588/4885L3MBTL1 842/4885
US-20250353836-A1 N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS TRPV1, SCN2A, SCN2B MAPK1 4157/4885KDM4E 3320/4885L3MBTL1 4523/4885
US-20260124222-A1 ISOTHIAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY MALT1, BCL6, BCL6B MAPK1 2541/4885KDM4E 2254/4885L3MBTL1 1165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.